Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01381887 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Effect of JNJ-28431754 (Canagliflozin) on Post-Meal Glucose in Patients With Type 2 Diabetes Mellitus
A Phase 1 study, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- Completed
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
NCT01381887 is a Phase 1 study that has completed, run by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. The registered enrollment target is 37 participants.
The verdict
NCT01381887, a Phase 1 study, has completed, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of canagliflozin on post-meal glucose blood levels in patients with Type 2 Diabetes Mellitus.
Interventions
- DRUG Placebo
- DRUG Canagliflozin 300mg/Placebo
- DRUG Canagliflozin 300mg/Canagliflozin 150mg
- DRUG Canagliflozin 300mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2011-06 |
| Est. Completion | 2011-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01381887
The ClinicalTrials.gov registry entry for NCT01381887 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01381887 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01381887 about?
NCT01381887 is a clinical study titled "A Study to Evaluate the Effect of JNJ-28431754 (Canagliflozin) on Post-Meal Glucose in Patients With Type 2 Diabetes Mellitus". The purpose of this study is to evaluate the effect of canagliflozin on post-meal glucose blood levels in patients with Type 2 Diabetes Mellitus.
What is the current status of trial NCT01381887?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2011-06. Estimated completion is 2011-11.
What interventions are being tested in trial NCT01381887?
The interventions under investigation include: Placebo (DRUG), Canagliflozin 300mg/Placebo (DRUG), Canagliflozin 300mg/Canagliflozin 150mg (DRUG), Canagliflozin 300mg (DRUG).
Who is sponsoring clinical trial NCT01381887?
This trial is sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.